Randomized Controlled Trial of Aquablation versus Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia: One-year Outcomes

Peter J. Gilling, Neil Barber, Mohamed Bidair, Paul Anderson, Mark Sutton, Tev Aho, Eugene Kramolowsky, Andrew Thomas, Barrett Cowan, Claus Roehrborn

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: To report 1-year safety and efficacy outcomes after either Aquablation or transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia (BPH) Methods: This double-blinded, multicenter prospective randomized controlled trial assigned 181 patients with BPH-related moderate-to-severe lower urinary tract symptoms to either electrocautery-based prostate resection (TURP) or Aquablation. Efficacy endpoints included reduction in International Prostate Symptom Score and improvement in uroflow parameters. The primary safety endpoint was the occurrence of Clavien-Dindo persistent grade 1 or grade 2 or higher complications. Results: BPH symptom score improvements were similar across groups with 12-month reduction of 15.1 points after TURP or Aquablation. In both groups, mean maximum urinary flow rates increased markedly postoperatively, with mean improvements of 10.3 cc/s for Aquablation versus 10.6 cc/s for TURP (P =.8632). At 1 year, Prostate-specific antigen (PSA) was reduced significantly (P <.01) in both groups by 1 point; the reduction was similar across groups (P =.9125). Surgical retreatment for BPH rates for TURP were 1.5% and Aquablation 2.6% within 1 year from the study procedure (P = not significant (NS)). The rate of late complications was low, with no procedure-related adverse events after month 6. Conclusion: The 1-year outcomes after TURP and Aquablation were similar and the rate of late procedure-related complications was low. (ClinicalTrials.gov number, NCT02505919).

Original languageEnglish (US)
JournalUrology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Transurethral Resection of Prostate
Prostatic Hyperplasia
Randomized Controlled Trials
Lower Urinary Tract Symptoms
Prostate
Safety
Electrocoagulation
Retreatment
Prostate-Specific Antigen

ASJC Scopus subject areas

  • Urology

Cite this

Randomized Controlled Trial of Aquablation versus Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia : One-year Outcomes. / Gilling, Peter J.; Barber, Neil; Bidair, Mohamed; Anderson, Paul; Sutton, Mark; Aho, Tev; Kramolowsky, Eugene; Thomas, Andrew; Cowan, Barrett; Roehrborn, Claus.

In: Urology, 01.01.2019.

Research output: Contribution to journalArticle

Gilling, Peter J. ; Barber, Neil ; Bidair, Mohamed ; Anderson, Paul ; Sutton, Mark ; Aho, Tev ; Kramolowsky, Eugene ; Thomas, Andrew ; Cowan, Barrett ; Roehrborn, Claus. / Randomized Controlled Trial of Aquablation versus Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia : One-year Outcomes. In: Urology. 2019.
@article{b1447b20221b4e1ea12871b1d7563952,
title = "Randomized Controlled Trial of Aquablation versus Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia: One-year Outcomes",
abstract = "Objective: To report 1-year safety and efficacy outcomes after either Aquablation or transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia (BPH) Methods: This double-blinded, multicenter prospective randomized controlled trial assigned 181 patients with BPH-related moderate-to-severe lower urinary tract symptoms to either electrocautery-based prostate resection (TURP) or Aquablation. Efficacy endpoints included reduction in International Prostate Symptom Score and improvement in uroflow parameters. The primary safety endpoint was the occurrence of Clavien-Dindo persistent grade 1 or grade 2 or higher complications. Results: BPH symptom score improvements were similar across groups with 12-month reduction of 15.1 points after TURP or Aquablation. In both groups, mean maximum urinary flow rates increased markedly postoperatively, with mean improvements of 10.3 cc/s for Aquablation versus 10.6 cc/s for TURP (P =.8632). At 1 year, Prostate-specific antigen (PSA) was reduced significantly (P <.01) in both groups by 1 point; the reduction was similar across groups (P =.9125). Surgical retreatment for BPH rates for TURP were 1.5{\%} and Aquablation 2.6{\%} within 1 year from the study procedure (P = not significant (NS)). The rate of late complications was low, with no procedure-related adverse events after month 6. Conclusion: The 1-year outcomes after TURP and Aquablation were similar and the rate of late procedure-related complications was low. (ClinicalTrials.gov number, NCT02505919).",
author = "Gilling, {Peter J.} and Neil Barber and Mohamed Bidair and Paul Anderson and Mark Sutton and Tev Aho and Eugene Kramolowsky and Andrew Thomas and Barrett Cowan and Claus Roehrborn",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.urology.2018.12.002",
language = "English (US)",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Randomized Controlled Trial of Aquablation versus Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia

T2 - One-year Outcomes

AU - Gilling, Peter J.

AU - Barber, Neil

AU - Bidair, Mohamed

AU - Anderson, Paul

AU - Sutton, Mark

AU - Aho, Tev

AU - Kramolowsky, Eugene

AU - Thomas, Andrew

AU - Cowan, Barrett

AU - Roehrborn, Claus

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: To report 1-year safety and efficacy outcomes after either Aquablation or transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia (BPH) Methods: This double-blinded, multicenter prospective randomized controlled trial assigned 181 patients with BPH-related moderate-to-severe lower urinary tract symptoms to either electrocautery-based prostate resection (TURP) or Aquablation. Efficacy endpoints included reduction in International Prostate Symptom Score and improvement in uroflow parameters. The primary safety endpoint was the occurrence of Clavien-Dindo persistent grade 1 or grade 2 or higher complications. Results: BPH symptom score improvements were similar across groups with 12-month reduction of 15.1 points after TURP or Aquablation. In both groups, mean maximum urinary flow rates increased markedly postoperatively, with mean improvements of 10.3 cc/s for Aquablation versus 10.6 cc/s for TURP (P =.8632). At 1 year, Prostate-specific antigen (PSA) was reduced significantly (P <.01) in both groups by 1 point; the reduction was similar across groups (P =.9125). Surgical retreatment for BPH rates for TURP were 1.5% and Aquablation 2.6% within 1 year from the study procedure (P = not significant (NS)). The rate of late complications was low, with no procedure-related adverse events after month 6. Conclusion: The 1-year outcomes after TURP and Aquablation were similar and the rate of late procedure-related complications was low. (ClinicalTrials.gov number, NCT02505919).

AB - Objective: To report 1-year safety and efficacy outcomes after either Aquablation or transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia (BPH) Methods: This double-blinded, multicenter prospective randomized controlled trial assigned 181 patients with BPH-related moderate-to-severe lower urinary tract symptoms to either electrocautery-based prostate resection (TURP) or Aquablation. Efficacy endpoints included reduction in International Prostate Symptom Score and improvement in uroflow parameters. The primary safety endpoint was the occurrence of Clavien-Dindo persistent grade 1 or grade 2 or higher complications. Results: BPH symptom score improvements were similar across groups with 12-month reduction of 15.1 points after TURP or Aquablation. In both groups, mean maximum urinary flow rates increased markedly postoperatively, with mean improvements of 10.3 cc/s for Aquablation versus 10.6 cc/s for TURP (P =.8632). At 1 year, Prostate-specific antigen (PSA) was reduced significantly (P <.01) in both groups by 1 point; the reduction was similar across groups (P =.9125). Surgical retreatment for BPH rates for TURP were 1.5% and Aquablation 2.6% within 1 year from the study procedure (P = not significant (NS)). The rate of late complications was low, with no procedure-related adverse events after month 6. Conclusion: The 1-year outcomes after TURP and Aquablation were similar and the rate of late procedure-related complications was low. (ClinicalTrials.gov number, NCT02505919).

UR - http://www.scopus.com/inward/record.url?scp=85059450593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059450593&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2018.12.002

DO - 10.1016/j.urology.2018.12.002

M3 - Article

C2 - 30552937

AN - SCOPUS:85059450593

JO - Urology

JF - Urology

SN - 0090-4295

ER -